Delcath Systems (NASDAQ:DCTH – Get Free Report) and Neogen (NASDAQ:NEOG – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.
Risk & Volatility
Delcath Systems has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Neogen has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500.
Valuation & Earnings
This table compares Delcath Systems and Neogen”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Delcath Systems | $85.23 million | 6.01 | $2.70 million | $0.01 | 1,475.00 |
| Neogen | $870.40 million | 3.00 | -$7.90 million | ($0.25) | -47.92 |
Delcath Systems has higher earnings, but lower revenue than Neogen. Neogen is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and price targets for Delcath Systems and Neogen, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Delcath Systems | 0 | 2 | 3 | 0 | 2.60 |
| Neogen | 1 | 1 | 3 | 0 | 2.40 |
Delcath Systems presently has a consensus target price of $24.50, suggesting a potential upside of 66.10%. Neogen has a consensus target price of $12.67, suggesting a potential upside of 5.73%. Given Delcath Systems’ stronger consensus rating and higher probable upside, research analysts plainly believe Delcath Systems is more favorable than Neogen.
Insider & Institutional Ownership
61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 96.7% of Neogen shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by company insiders. Comparatively, 0.5% of Neogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Delcath Systems and Neogen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Delcath Systems | 0.56% | 0.46% | 0.42% |
| Neogen | -6.35% | 3.29% | 2.06% |
Summary
Delcath Systems beats Neogen on 8 of the 13 factors compared between the two stocks.
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
About Neogen
Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods. The segment offers its products primarily to milling and grain, meat and poultry, prepared foods and ingredients, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products, and genomics testing services marketed through veterinarians, retailers, livestock producers, and animal health product distributors, for the animal safety market. The segment offers its products for companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.
